Update on the Management of Infectious Keratitis

Ophthalmology

Volumn 124, Issue 11, 2017, Pages 1678-1689

  Austin, Ariana ^a   Lietman, Tom ^a   Rose Nussbaumer, Jennifer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COLLAGENASE; DOXYCYCLINE; MATRIX METALLOPROTEINASE; STEROID; TETRACYCLINE DERIVATIVE; VORICONAZOLE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; GLUCOCORTICOID;

BACTERIAL KERATITIS; CROSS LINKING; FUTUROLOGY; HUMAN; INFECTION PREVENTION; KERATITIS; KERATOMYCOSIS; MULTICENTER STUDY (TOPIC); NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TOPICAL TREATMENT; VIRUS KERATITIS; CORNEAL ULCER; EYE INFECTIONS, BACTERIAL; EYE INFECTIONS, FUNGAL; FEMALE; KERATITIS, HERPETIC; MALE; MICROBIOLOGY; PHYSIOLOGY; VIROLOGY; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; CORNEAL ULCER; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; EYE INFECTIONS, BACTERIAL; EYE INFECTIONS, FUNGAL; FEMALE; GLUCOCORTICOIDS; HUMANS; KERATITIS, HERPETIC; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VISUAL ACUITY;

EID: 85029642138     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2017.05.012     Document Type: Review

References (130)

1. Whitcher, J.P., Srinivasan, M., Upadhyay, M.P., Corneal blindness: a global perspective. Bull World Health Organ 79 (2001), 214–221.
2. Pascolini, D., Mariotti, S.P., Global estimates of visual impairment: 2010. Br J Ophthalmol 96 (2012), 614–618.
3. World Health Organization. Causes of blindness and visual impairment. Available at: http://www.who.int/blindness/causes/en Accessed December 7, 2016.
4. Gupta, N., Tandon, R., Gupta, S.K., et al. Burden of corneal blindness in India. Indian J Community Med 38 (2013), 198–206.
5. Gonzales, C.A., Srinivasan, M., Whitcher, J.P., Smolin, G., Incidence of corneal ulceration in Madurai district, South India. Ophthalmic Epidemiol 3 (1996), 159–166.
6. Dart, J.K., Stapleton, F., Minassian, D., Contact lenses and other risk factors in microbial keratitis. Lancet 338 (1991), 650–653.
7. Green, M., Apel, A., Stapleton, F., Risk factors and causative organisms in microbial keratitis. Cornea 27 (2008), 22–27.
8. Keay, L., Stapleton, F., Schein, O., Epidemiology of contact lens-related inflammation and microbial keratitis: a 20-year perspective. Eye Contact Lens 33:6 Pt 2 (2007), 346–353 discussion 362-363.
9. Thylefors, B., Epidemiological patterns of ocular trauma. Aust N Z J Ophthalmol 20 (1992), 95–98.
10. Sheng, X.L., Li, H.P., Liu, Q.X., et al. Prevalence and associated factors of corneal blindness in Ningxia in northwest China. Int J Ophthalmol 7 (2014), 557–562.
11. Saha, S., Banerjee, D., Khetan, A., Sengupta, J., Epidemiological profile of fungal keratitis in urban population of West Bengal, India. Oman J Ophthalmol 2 (2009), 114–118.
12. Nirmalan, P.K., Katz, J., Tielsch, J.M., et al. Ocular trauma in a rural south Indian population: the Aravind Comprehensive Eye Survey. Ophthalmology 111 (2004), 1778–1781.
13. McLeod, S.D., Kolahdouz-Isfahani, A., Rostamian, K., et al. The role of smears, cultures, and antibiotic sensitivity testing in the management of suspected infectious keratitis. Ophthalmology 103 (1996), 23–28.
14. Kim, E., Chidambaram, J.D., Srinivasan, M., et al. Prospective comparison of microbial culture and polymerase chain reaction in the diagnosis of corneal ulcer. Am J Ophthalmol 146 (2008), 714–723 723.e711.
15. Chang, H.Y., Chodosh, J., Diagnostic and therapeutic considerations in fungal keratitis. Int Ophthalmol Clin 51 (2011), 33–42.
16. Badiee, P., Nejabat, M., Alborzi, A., et al. Comparative study of Gram stain, potassium hydroxide smear, culture and nested PCR in the diagnosis of fungal keratitis. Ophthalmic Res 44 (2010), 251–256.
17. Zhang, W., Yang, H., Jiang, L., et al. Use of potassium hydroxide, Giemsa and calcofluor white staining techniques in the microscopic evaluation of corneal scrapings for diagnosis of fungal keratitis. J Int Med Res 38 (2010), 1961–1967.
18. Gopinathan, U., Sharma, S., Garg, P., Rao, G.N., Review of epidemiological features, microbiological diagnosis and treatment outcome of microbial keratitis: experience of over a decade. Indian J Ophthalmol 57 (2009), 273–279.
19. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. Bacterial Keratitis. 2013, American Academy of Ophthalmology, San Francisco, CA Available at: www.aao.org/ppp.
20. Darougar, S., Wishart, M.S., Viswalingam, N.D., Epidemiological and clinical features of primary herpes simplex virus ocular infection. Br J Ophthalmol 69 (1985), 2–6.
21. El-Aal, A.M., El Sayed, M., Mohammed, E., et al. Evaluation of herpes simplex detection in corneal scrapings by three molecular methods. Curr Microbiol 52 (2006), 379–382.
22. Nielsen, E., Heegaard, S., Prause, J.U., et al. Fungal keratitis—improving diagnostics by confocal microscopy. Case Rep Ophthalmol 4 (2013), 303–310.
23. Avunduk, A.M., Beuerman, R.W., Varnell, E.D., Kaufman, H.E., Confocal microscopy of Aspergillus fumigatus keratitis. Br J Ophthalmol 87 (2003), 409–410.
24. Das, S., Samant, M., Garg, P., et al. Role of confocal microscopy in deep fungal keratitis. Cornea 28 (2009), 11–13.
25. Kanavi, M.R., Javadi, M., Yazdani, S., Mirdehghanm, S., Sensitivity and specificity of confocal scan in the diagnosis of infectious keratitis. Cornea 26 (2007), 782–786.
26. Vaddavalli, P.K., Garg, P., Sharma, S., et al. Role of confocal microscopy in the diagnosis of fungal and acanthamoeba keratitis. Ophthalmology 118 (2011), 29–35.
27. Konstantopoulos, A., Kuo, J., Anderson, D., Hossain, P., Assessment of the use of anterior segment optical coherence tomography in microbial keratitis. Am J Ophthalmol 146 (2008), 534–542.
28. Martone, G., Pichierri, P., Franceschini, R., et al. In vivo confocal microscopy and anterior segment optical coherence tomography in a case of alternaria keratitis. Cornea 30 (2011), 449–453.
29. Austin A, Schallhorn J, Geske M, et al. Empiric treatment of bacterial keratitis: an international survey of corneal specialists. Br J Ophthalmol Open. [Accepted for publication].
30. McDonald, E.M., Ram, F.S., Patel, D.V., McGhee, C.N., Topical antibiotics for the management of bacterial keratitis: an evidence-based review of high quality randomised controlled trials. Br J Ophthalmol 98 (2014), 1470–1477.
31. Constantinou, M., Daniell, M., Snibson, G.R., et al. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial. Ophthalmology 114 (2007), 1622–1629.
32. O'Brien, T.P., Maguire, M.G., Fink, N.E., et al. Efficacy of ofloxacin vs. cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol 113 (1995), 1257–1265.
33. Hyndiuk, R.A., Eiferman, R.A., Caldwell, D.R., et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology 103 (1996), 1854–1863.
34. The Ofloxacin Study Group.Ofloxacin monotherapy for the primary treatment of microbial keratitis: a double-masked, randomized, controlled trial with conventional dual therapy. Ophthalmology 104 (1997), 1902–1909.
35. Team, E.E., CDC publishes report on antibiotic resistance threats in the United States for the first time. Eurosurveillance, 18, 2013 28-28.
36. Asbell, P.A., Colby, K.A., Deng, S., et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 145 (2008), 951–958.
37. Haas, W., Pillar, C.M., Torres, M., et al. Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study. Am J Ophthalmol 152 (2011), 567–574.e563.
38. Alster, Y., Herlin, L., Lazar, M., Loewenstein, A., Intraocular penetration of vancomycin eye drops after application to the medial canthus with closed lids. Br J Ophthalmol 84 (2000), 300–302.
39. Ray, K.J., Prajna, L., Srinivasan, M., et al. Fluoroquinolone treatment and susceptibility of isolates from bacterial keratitis. JAMA Ophthalmol 131 (2013), 310–313.
40. Oldenburg, C.E., Lalitha, P., Srinivasan, M., et al. Moxifloxacin susceptibility mediates the relationship between causative organism and clinical outcome in bacterial keratitis. Invest Ophthalmol Vis Sci 54 (2013), 1522–1526.
41. Lalitha, P., Srinivasan, M., Manikandan, P., et al. Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis. Clin Infect Dis 54 (2012), 1381–1387.
42. Burns, F.R., Stack, M.S., Gray, R.D., Paterson, C.A., Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci 30 (1989), 1569–1575.
43. Golub, L.M., Sorsa, T., Lee, H.M., et al. Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. J Clin Periodontol 22 (1995), 100–109.
44. Dursun, D., Kim, M.C., Solomon, A., Pflugfelder, S.C., Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. Am J Ophthalmol 132 (2001), 8–13.
45. Seedor, J.A., Perry, H.D., McNamara, T.F., et al. Systemic tetracycline treatment of alkali-induced corneal ulceration in rabbits. Arch Ophthalmol 105 (1987), 268–271.
46. Levy, J.H., Katz, H.R., Effect of systemic tetracycline on progression of Pseudomonas aeruginosa keratitis in the rabbit. Ann Ophthalmol 22 (1990), 179–183.
47. Acharya, N.R., Srinivasan, M., Mascarenhas, J., et al. The steroid controversy in bacterial keratitis. Arch Ophthalmol, 127, 2009, 1231.
48. Cohen, E.J., The case against the use of steroids in the treatment of bacterial keratitis. Arch Ophthalmol 127 (2009), 103–104.
49. Hindman, H.B., Patel, S.B., Jun, A.S., Rationale for adjunctive topical corticosteroids in bacterial keratitis. Arch Ophthalmol 127 (2009), 97–102.
50. Den, S., Sotozono, C., Kinoshita, S., Ikeda, T., Efficacy of early systemic betamethasone or cyclosporin A after corneal alkali injury via inflammatory cytokine reduction. Acta Ophthalmol Scand 82 (2004), 195–199.
51. Yi, K., Chung, T.Y., Hyon, J.Y., et al. Combined treatment with antioxidants and immunosuppressants on cytokine release by human peripheral blood mononuclear cells—chemically injured keratocyte reaction. Mol Vis 17 (2011), 2665–2671.
52. Williams, R.N., Paterson, C.A., The influence of topical corticosteroid therapy upon polymorphonuclear leukocyte distribution, vascular integrity and ascorbate levels in endotoxin-induced inflammation of the rabbit eye. Exp Eye Res 44 (1987), 191–198.
53. Chung, J.H., Kang, Y.G., Kim, H.J., Effect of 0.1% dexamethasone on epithelial healing in experimental corneal alkali wounds: morphological changes during the repair process. Graefes Arch Clin Exp Ophthalmol 236 (1998), 537–545.
54. Tomas-Barberan, S., Fagerholm, P., Influence of topical treatment on epithelial wound healing and pain in the early postoperative period following photorefractive keratectomy. Acta Ophthalmol Scand 77 (1999), 135–138.
55. Gritz, D.C., Kwitko, S., Trousdale, M.D., et al. Recurrence of microbial keratitis concomitant with antiinflammatory treatment in an animal model. Cornea 11 (1992), 404–408.
56. Gritz, D.C., Lee, T.Y., Kwitko, S., McDonnell, P.J., Topical anti-inflammatory agents in an animal model of microbial keratitis. Arch Ophthalmol 108 (1990), 1001–1005.
57. Herretes, S., Wang, X., Reyes, J.M., Topical corticosteroids as adjunctive therapy for bacterial keratitis. Cochrane Database Syst Rev, 2014, CD005430.
58. Blair, J., Hodge, W., Al-Ghamdi, S., et al. Comparison of antibiotic-only and antibiotic-steroid combination treatment in corneal ulcer patients: double-blinded randomized clinical trial. Can J Ophthalmol 46 (2011), 40–45.
59. Carmichael, T.R., Gelfand, Y., Welsh, N.H., Topical steroids in the treatment of central and paracentral corneal ulcers. Br J Ophthalmol 74 (1990), 528–531.
60. Srinivasan, M., Lalitha, P., Mahalakshmi, R., et al. Corticosteroids for bacterial corneal ulcers. Br J Ophthalmol 93 (2009), 198–202.
61. Srinivasan, M., Mascarenhas, J., Rajaraman, R., et al. Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT). Arch Ophthalmol 130 (2012), 143–150.
62. Ray, K.J., Srinivasan, M., Mascarenhas, J., et al. Early addition of topical corticosteroids in the treatment of bacterial keratitis. JAMA Ophthalmol 132 (2014), 737–741.
63. Lalitha, P., Srinivasan, M., Rajaraman, R., et al. Nocardia keratitis: clinical course and effect of corticosteroids. Am J Ophthalmol 154 (2012), 934–939.e931.
64. Srinivasan, M., Mascarenhas, J., Rajaraman, R., et al. The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial. Am J Ophthalmol 157 (2014), 327–333.e323.
65. Borkar, D.S., Fleiszig, S.M., Leong, C., et al. Association between cytotoxic and invasive Pseudomonas aeruginosa and clinical outcomes in bacterial keratitis. JAMA Ophthalmol 131 (2013), 147–153.
66. Gopinathan, U., Garg, P., Fernandes, M., et al. The epidemiological features and laboratory results of fungal keratitis: a 10-year review at a referral eye care center in South India. Cornea 21 (2002), 555–559.
67. Deorukhkar, S., Katiyar, R., Saini, S., Epidemiological features and laboratory results of bacterial and fungal keratitis: a five-year study at a rural tertiary-care hospital in western Maharashtra, India. Singapore Med J 53 (2012), 264–267.
68. Srinivasan, M., Gonzales, C.A., George, C., et al. Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, South India. Br J Ophthalmol 81 (1997), 965–971.
69. Alfonso, E., Mandelbaum, S., Fox, M.J., Forster, R.K., Ulcerative keratitis associated with contact lens wear. Am J Ophthalmol 101 (1986), 429–433.
70. Bernal, M.D., Acharya, N.R., Lietman, T.M., et al. Outbreak of Fusarium keratitis in soft contact lens wearers in San Francisco. Arch Ophthalmol 124 (2006), 1051–1053.
71. Gower, E.W., Keay, L.J., Oechsler, R.A., et al. Trends in fungal keratitis in the United States, 2001 to 2007. Ophthalmology 117 (2010), 2263–2267.
72. Tanure, M.A., Cohen, E.J., Sudesh, S., et al. Spectrum of fungal keratitis at Wills Eye Hospital, Philadelphia, Pennsylvania. Cornea 19 (2000), 307–312.
73. O'Day, D.M., Head, W.S., Robinson, R.D., Clanton, J.A., Corneal penetration of topical amphotericin B and natamycin. Curr Eye Res 5 (1986), 877–882.
74. Hariprasad, S.M., Mieler, W.F., Lin, T.K., et al. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol 92 (2008), 871–878.
75. Walsh, T.J., Pappas, P., Winston, D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346 (2002), 225–234.
76. Prajna, N.V., Krishnan, T., Mascarenhas, J., et al. The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs. voriconazole. JAMA Ophthalmol 131 (2013), 422–429.
77. Sharma, S., Das, S., Virdi, A., et al. Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial. Br J Ophthalmol 99 (2015), 1190–1195.
78. FlorCruz, N.V., Evans, J.R., Medical interventions for fungal keratitis. Cochrane Database Syst Rev, 2015, CD004241.
79. Thiel, M.A., Zinkernagel, A.S., Burhenne, J., et al. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother 51 (2007), 239–244.
80. Hernandez Prats, C., Llinares Tello, F., Burgos San Jose, A., et al. Voriconazole in fungal keratitis caused by Scedosporium apiospermum. Ann Pharmacother 38 (2004), 414–417.
81. Jones, A., Muhtaseb, M., Use of voriconazole in fungal keratitis. J Cataract Refract Surg 34 (2008), 183–184.
82. Prajna, N.V., Krishnan, T., Rajaraman, R., et al. Effect of oral voriconazole on fungal keratitis in the Mycotic Ulcer Treatment Trial II (MUTT II): a randomized clinical trial. JAMA Ophthalmol 134 (2016), 1365–1372.
83. Sharma, B., Kataria, P., Anand, R., et al. Efficacy profile of intracameral amphotericin B. The often forgotten step. Asia Pac J Ophthalmol (Phila) 4 (2015), 360–366.
84. Yoon, K.C., Jeong, I.Y., Im, S.K., et al. Therapeutic effect of intracameral amphotericin B injection in the treatment of fungal keratitis. Cornea 26 (2007), 814–818.
85. Kaushik, S., Ram, J., Brar, G.S., et al. Intracameral amphotericin B: initial experience in severe keratomycosis. Cornea 20 (2001), 715–719.
86. Kuriakose, T., Kothari, M., Paul, P., et al. Intracameral amphotericin B injection in the management of deep keratomycosis. Cornea 21 (2002), 653–656.
87. Sharma, N., Sankaran, P., Agarwal, T., et al. Evaluation of intracameral amphotericin B in the management of fungal keratitis: randomized controlled trial. Ocul Immunol Inflamm 24 (2016), 493–497.
88. Kalaiselvi, G., Narayana, S., Krishnan, T., Sengupta, S., Intrastromal voriconazole for deep recalcitrant fungal keratitis: a case series. Br J Ophthalmol 99 (2015), 195–198.
89. Prakash, G., Sharma, N., Goel, M., et al. Evaluation of intrastromal injection of voriconazole as a therapeutic adjunctive for the management of deep recalcitrant fungal keratitis. Am J Ophthalmol 146 (2008), 56–59.
90. Sharma, N., Agarwal, P., Sinha, R., et al. Evaluation of intrastromal voriconazole injection in recalcitrant deep fungal keratitis: case series. Br J Ophthalmol 95 (2011), 1735–1737.
91. Farooq, A.V., Shukla, D., Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv Ophthalmol 57 (2012), 448–462.
92. Liesegang, T.J., Melton, L.J. 3rd, Daly, P.J., Ilstrup, D.M., Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol 107 (1989), 1155–1159.
93. Reynaud, C., Rousseau, A., Kaswin, G., et al. Persistent impairment of quality of life in patients with herpes simplex keratitis. Ophthalmology 124 (2017), 160–169.
94. Morfin, F., Thouvenot, D., Herpes simplex virus resistance to antiviral drugs. J Clin Virol 26 (2003), 29–37.
95. Tsatsos, M., MacGregor, C., Athanasiadis, I., et al. Herpes simplex virus keratitis: an update of the pathogenesis and current treatment with oral and topical antiviral agents. Clin Exp Ophthalmol 44 (2016), 824–837.
96. Chou, T.Y., Hong, B.Y., Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications. Ther Clin Risk Manag 10 (2014), 665–681.
97. Colin, J., Hoh, H.B., Easty, D.L., et al. Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis. Cornea 16 (1997), 393–399.
98. Wilhelmus, K.R., Gee, L., Hauck, W.W., et al. Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology 101 (1994), 1883–1896.
99. Barron, B.A., Gee, L., Hauck, W.W., et al. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology 101 (1994), 1871–1882.
100. Goldblum, D., Bachmann, C., Tappeiner, C., et al. Comparison of oral antiviral therapy with valacyclovir or acyclovir after penetrating keratoplasty for herpetic keratitis. Br J Ophthalmol 92 (2008), 1201–1205.
101. Dias, C., Nashed, Y., Atluri, H., Mitra, A., Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: an evaluation using ocular microdialysis and LC-MS. Curr Eye Res 25 (2002), 243–252.
102. Razonable, R.R., Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc 86 (2011), 1009–1026.
103. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group. N Engl J Med 339 (1998), 300–306.
104. Thomas, S.L., Wheeler, J.G., Hall, A.J., Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 360 (2002), 678–682.
105. Lalitha, P., Prajna, N.V., Manoharan, G., et al. Trends in bacterial and fungal keratitis in South India, 2002–2012. Br J Ophthalmol 99 (2015), 192–194.
106. Papaioannou, L., Miligkos, M., Papathanassiou, M., Corneal collagen cross-linking for infectious keratitis: a systematic review and meta-analysis. Cornea 35 (2016), 62–71.
107. Iseli, H.P., Thiel, M.A., Hafezi, F., et al. Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts. Cornea 27 (2008), 590–594.
108. Keating, A., Pineda, R. 2nd, Colby, K., Corneal cross linking for keratoconus. Semin Ophthalmol 25 (2010), 249–255.
109. Lamy, R., Netto, C.F., Reis, R.G., et al. Effects of corneal cross-linking on contrast sensitivity, visual acuity, and corneal topography in patients with keratoconus. Cornea 32 (2013), 591–596.
110. Raiskup-Wolf, F., Hoyer, A., Spoerl, E., Pillunat, L.E., Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg 34 (2008), 796–801.
111. Vinciguerra, P., Albe, E., Trazza, S., et al. Intraoperative and postoperative effects of corneal collagen cross-linking on progressive keratoconus. Arch Ophthalmol 127 (2009), 1258–1265.
112. Alio, J.L., Abbouda, A., Valle, D.D., et al. Corneal cross-linking and infectious keratitis: a systematic review with a meta-analysis of reported cases. J Ophthalmic Inflamm Infect, 3, 2013, 47.
113. Martins, S.A., Combs, J.C., Noguera, G., et al. Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis. Invest Ophthalmol Vis Sci 49 (2008), 3402–3408.
114. Panda, A., Krishna, S.N., Kumar, S., Photo-activated riboflavin therapy of refractory corneal ulcers. Cornea 31 (2012), 1210–1213.
115. Makdoumi, K., Mortensen, J., Crafoord, S., Infectious keratitis treated with corneal crosslinking. Cornea 29 (2010), 1353–1358.
116. Shetty, R., Nagaraja, H., Jayadev, C., et al. Collagen crosslinking in the management of advanced non-resolving microbial keratitis. Br J Ophthalmol 98 (2014), 1033–1035.
117. Makdoumi, K., Mortensen, J., Sorkhabi, O., et al. UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study. Graefes Arch Clin Exp Ophthalmol 250 (2012), 95–102.
118. Sauer, A., Letscher-Bru, V., Speeg-Schatz, C., et al. In vitro efficacy of antifungal treatment using riboflavin/UV-A (365 nm) combination and amphotericin B. Invest Ophthalmol Vis Sci 51 (2010), 3950–3953.
119. Bamdad, S., Malekhosseini, H., Khosravi, A., Ultraviolet A/riboflavin collagen cross-linking for treatment of moderate bacterial corneal ulcers. Cornea 34 (2015), 402–406.
120. Said, D.G., Elalfy, M.S., Gatzioufas, Z., et al. Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting. Ophthalmology 121 (2014), 1377–1382.
121. Mittal, R., Garg, P., Re: Said et al.: Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting (Ophthalmology. 2014;121:1377-82). Ophthalmology 121 (2014), e67–e68.
122. Uddaraju, M., Mascarenhas, J., Das, M.R., et al. Corneal cross-linking as an adjuvant therapy in the management of recalcitrant deep stromal fungal keratitis: a randomized trial. Am J Ophthalmol 160 (2015), 131–134.e135.
123. Dehghani, A.R., Fazel, F., Akhlaghi, M.R., et al. Cefazolin-gentamicin versus vancomycin-ceftazidime eye drops for bacterial corneal ulcers; a randomized clinical trial. J Ophthalm Vis Res 4 (2009), 19–23.
124. Kasetsuwan, N., Tanthuvanit, P., Reinprayoon, U., The efficacy and safety of 0.5% levofloxacin versus fortified cefazolin and amikacin ophthalmic solution for the treatment of suspected and culture-proven cases of infectious bacterial keratitis: a comparative study. Asian Biomed 5 (2011), 77–83.
125. Panda, A., Ahuja, R., Sastry, S.S., Comparison of topical 0.3% ofloxacin with fortified tobramycin plus cefazolin in the treatment of bacterial keratitis. Eye 13:Pt 6 (1999), 744–747.
126. Parmar, P., Salman, A., Kalavathy, C.M., et al. Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis. Am J Ophthalmol 141 (2006), 282–286.
127. Prajna, N.V., George, C., Selvaraj, S., et al. Bacteriologic and clinical efficacy of ofloxacin 0.3% versus ciprofloxacin 0.3% ophthalmic solutions in the treatment of patients with culture-positive bacterial keratitis. Cornea 20 (2001), 175–178.
128. Shah, V.M., Tandon, R., Satpathy, G., et al. Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers. Cornea 29 (2010), 751–757.
129. Sharma, N., Goel, M., Bansal, S., et al. Evaluation of moxifloxacin 0.5% in treatment of nonperforated bacterial corneal ulcers: a randomized controlled trial. Ophthalmology 120 (2013), 1173–1178.
130. Prajna, N.V., Mascarenhas, J., Krishnan, T., et al. Comparison of natamycin and voriconazole for the treatment of fungal keratitis. Arch Ophthalmol 128 (2010), 672–678.